Van Hulzen Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Van Hulzen Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1,000	Closed	-$105K	–	147
2015 Q4	$105K	Hold	1,000	–	–	0.07%	134
2015 Q3	$105K	Buy	+1,000	New	+$134K	0.07%	135

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Van Hulzen Asset Management's BMRN Position: Q1 2016 in Review

Van Hulzen Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 1,000 shares — an estimated $105K sold.

Van Hulzen Asset Management first reported a position in BMRN in Q3 2015 and held it in 2 quarters. The position peaked at $105K in Q4 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

Van Hulzen Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Van Hulzen Asset Management sold 1,000 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $105K.
Van Hulzen Asset Management first reported a position in BioMarin Pharmaceuticals in Q3 2015 and held it in 2 quarters.
Van Hulzen Asset Management's BioMarin Pharmaceuticals position peaked at $105K in Q4 2015.
390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Van Hulzen Asset Management's 13F filing for Q1 2016, filed 27 Apr 2016.